SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that results from nonclinical studies of its lead candidate biafungin™, a novel, long-acting echinocandin, will be presented this week at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C. Four posters and one abstract regarding biafungin have been accepted for presentation.
Kieren Marr, M.D., professor of medicine and oncology, and director of the transplant and oncology infectious diseases program at the Johns Hopkins University School of Medicine and advisor to Cidara, stated, “There remains significant unmet need for novel drugs to treat life-threatening, invasive fungal infections. A long-acting echinocandin would represent a major addition to our antifungal repertoire by enabling easier completion of treatment without antifungal class switching, potentially enabling earlier discharge of patients and better prevention strategies in high risk patients.”
Hey, check out all the research scientist jobs. Post your resume today!
